Bethan Psaila

9.8k total citations · 3 hit papers
61 papers, 5.5k citations indexed

About

Bethan Psaila is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Bethan Psaila has authored 61 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hematology, 29 papers in Genetics and 17 papers in Molecular Biology. Recurrent topics in Bethan Psaila's work include Platelet Disorders and Treatments (26 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (17 papers) and Blood groups and transfusion (14 papers). Bethan Psaila is often cited by papers focused on Platelet Disorders and Treatments (26 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (17 papers) and Blood groups and transfusion (14 papers). Bethan Psaila collaborates with scholars based in United Kingdom, United States and Australia. Bethan Psaila's co-authors include David Lyden, Rosandra N. Kaplan, James B. Bussel, J.M. Jenkins, Drew Provan, Sachie Hiratsuka, Amato J. Giaccia, Gonçalo Rodrigues, Nicole L. Stone and Bhabita Mayer and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Bethan Psaila

54 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pre-metastatic niches: organ-specific homes for metastases

2017 1.4k citations Bethan Psaila, Rosandra N. Kaplan et al. profile →
The metastatic niche: adapting the foreign soil

2009 980 citations Bethan Psaila, David Lyden profile →
Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura

2007 565 citations James B. Bussel, Gregory Cheng et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Bethan Psaila

Since Specialization

Citations

This map shows the geographic impact of Bethan Psaila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bethan Psaila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bethan Psaila more than expected).

Fields of papers citing papers by Bethan Psaila

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bethan Psaila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bethan Psaila. The network helps show where Bethan Psaila may publish in the future.

Co-authorship network of co-authors of Bethan Psaila

This figure shows the co-authorship network connecting the top 25 collaborators of Bethan Psaila. A scholar is included among the top collaborators of Bethan Psaila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bethan Psaila. Bethan Psaila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Generating human bone marrow organoids for disease modeling and drug discovery 2024 ·Nature Protocols ·Aude-Anaïs Olijnik, (unknown), Zoë C. Wong, (unknown), Jasmeet S. Reyat, Natalie J. Jooss, Julie Rayes, Bethan Psaila, Abdullah O. Khan	19
2	Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib 2024 ·Blood ·Adam J. Mead, Brian J.P. Huntly, Bethan Psaila, (unknown), Rebecca H. Boucher, Jiayi Wang, (unknown), Zsófia Brigitta Nagy, R. G. Record	0
3	Modelling the pathology and treatment of cardiac fibrosis in vascularised atrial and ventricular cardiac microtissues 2023 ·Frontiers in Cardiovascular Medicine ·Jasmeet S. Reyat, Alessandro Di Maio, Beata Grygielska, Jeremy A. Pike, Samuel Kemble, (unknown), Christina Simoglou Karali, Adam P. Croft, Bethan Psaila, Filipa C. Simões, Julie Rayes, Abdullah O. Khan	4
4	In utero origin of myelofibrosis presenting in adult monozygotic twins 2022 ·Nature Medicine ·Nikolaos Sousos, Máire Ní Leathlobhair, Christina Simoglou Karali, Eleni Louka, Nicola Bienz, Daniel Royston, Sally‐Ann Clark, Angela Hamblin, (unknown), Vikram Mathews, Biju George, Anindita Roy, Bethan Psaila, David C. Wedge, Adam J. Mead	33
5	Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development 2021 ·Cell Reports ·Anindita Roy, Guanlin Wang, Deena Iskander, Sorcha O’Byrne, Natalina Elliott, Jennifer O’Sullivan, Gemma Buck, Elisabeth F. Heuston, Wei Wen, Alba Rodríguez-Meira, Hua Peng, Anastasios Karadimitris, Adam J. Mead, David M. Bodine, Irene Roberts, Bethan Psaila, Supat Thongjuea	34
6	Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021 2021 ·Haematologica ·Tariq I. Mughal, Bethan Psaila, Daniel J. DeAngelo, Giuseppe Saglio, Richard A. Van Etten, Jerald P. Radich	4
7	Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies 2020 ·Hematological Oncology ·Tariq I. Mughal, Naveen Pemmaraju, Bethan Psaila, Jerald P. Radich, Prithviraj Bose, Thomas Lion, Jean‐Jacques Kiladjian, Raajit K. Rampal, Tania Jain, (unknown), Abdulraheem Yacoub, Jörge E. Cortes, Ruben A. Mesa, Giuseppe Saglio, Richard A. Van Etten	1
8	The BET inhibitor CPI203 promotes ex vivo expansion of cord blood long-term repopulating HSCs and megakaryocytes 2020 ·Blood ·Hua Peng, Joanna Hester, (unknown), Rong Li, Bethan Psaila, Anindita Roy, Carole J. R. Bataille, Graham M. Wynne, Thomas Jackson, Thomas A. Milne, Angela J. Russell, James Davies, Irene Roberts, Fadi Issa, Suzanne M. Watt	20
9	Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator 2017 ·Blood ·Evangelia Vlachodimitropoulou, Yulin Chen, Maciej Garbowski, Pimpisid Koonyosying, Bethan Psaila, Martha Sola‐Visner, Nichola Cooper, Robert C. Hider, John B. Porter	94
10	Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways 2016 ·Genome biology ·Bethan Psaila, Nikolaos Barkas, Deena Iskander, Anindita Roy, Stacie Anderson, Neil Ashley, Valentina S. Caputo, Jens Lichtenberg, Sandra Loaiza, David M. Bodine, Anastasios Karadimitris, Adam J. Mead, Irene Roberts	98
11	Megakaryocytes, malignancy and bone marrow vascular niches 2011 ·Journal of Thrombosis and Haemostasis ·Bethan Psaila, David Lyden, Ian Roberts	55
12	EFFICACY AND SAFETY OF REPEATED INTERMITTENT TREATMENT WITH ELTROMBOPAG IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) 2008 ·Bethan Psaila, J B Bussel, Sandra Y. Vasey, Manuel Aivado, Beate Mayer, Nicole L. Stone, M. Arning	2
13	Refractory immune thrombocytopenic purpura: current strategies for investigation and management 2008 ·British Journal of Haematology ·Bethan Psaila, James B. Bussel	64
14	Eltrombopag, an oral platelet growth factor, for treatment of chronic immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial 2007 ·J B Bussel, Guang‐Shing Cheng, Mohammad Saleh, Bethan Psaila, Л. В. Ковалева, Nicole L. Stone, Bryan T. Mayer, Jason Jenkins, (unknown)	1
15	The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP 2007 ·British Journal of Haematology ·(unknown), Bethan Psaila, Drew Provan, John M. Hamilton, J.M. Jenkins, (unknown), Martin Lesser, James B. Bussel	124
16	Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura breakdown → 2007 ·New England Journal of Medicine ·James B. Bussel, Gregory Cheng, Mansoor N. Saleh, Bethan Psaila, Lidia Kovaleva, Balkis Meddeb, Janusz Kłoczko, Habib Hassani, Bhabita Mayer, Nicole L. Stone, M. Arning, Drew Provan, J.M. Jenkins	565
17	Niche-to-niche migration of bone-marrow-derived cells 2007 ·Trends in Molecular Medicine ·Rosandra N. Kaplan, Bethan Psaila, David Lyden	153
18	Immune Thrombocytopenic Purpura 2007 ·Hematology/Oncology Clinics of North America ·Bethan Psaila, James B. Bussel	65
19	Novel Thrombopoietic Agents 2007 ·Hematology ·Biree Andemariam, Bethan Psaila, James B. Bussel	14
20	Hospital staff should use more than one method to detect adverse events and potential adverse events: incident reporting, pharmacist surveillance and local real-time record review may all have a place 2007 ·BMJ Quality & Safety ·S. Olsen, G. Neale, K. Schwab, Bethan Psaila, (unknown), Emma Chapman, Charles Vincent	152

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact